Otsuka and Lundbeck’s antidepressant Rexulti should be approved to treat Alzheimer’s disease-related agitation (AAD), according to FDA advisors – a move that could unlock a sizeable new ...

Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodegenerative disorder.

The FDA states that this practice can be dangerous for the elderly. In 2023, Otsuka Pharmaceuticals’ Rexulti (brexpiprazole) became the first FDA-approved treatment for agitation associated with ...